{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-24-000036","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.761804+00:00","generated_at":"2026-05-31T13:28:09.896043+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system","bullets":["FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.","Targets soft launch in late 2024 and full commercial launch in 2025.","Company focusing on operational readiness: product manufacturing and inventory levels for U.S. launch.","CEO cites FDA approval as a key milestone for Inspire therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-24-000036","json":"https://secwatch.observer/filing/0001609550-24-000036.json","markdown":"https://secwatch.observer/filing/0001609550-24-000036.md","text":"https://secwatch.observer/filing/0001609550-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000036/0001609550-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000036/insp-20240802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:28:09.896043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}